GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as antiretroviral therapy (ART), are highly effective at suppressing the virus and ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...